Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The mechanisms by which common genetic variation predisposes to type 2 diabetes remain unclear. The disease-associated variants in TCF7L2 (rs7903146) and WFS1 (rs10010131) have been shown to affect response to exogenous glucagon-like peptide 1 (GLP-1), while variants in KCNQ1 (rs151290, rs2237892, and rs2237895) alter endogenous GLP-1 secretion. We set out to validate these observations using a model of GLP-1–induced insulin secretion. We studied healthy individuals using a hyperglycemic clamp and GLP-1 infusion. In addition, we measured active and total GLP-1 in response to an oral challenge in nondiabetic subjects. After genotyping the relevant single nucleotide polymorphisms, generalized linear regression models and repeated-measures ANCOVA models incorporating potential confounders, such as age and BMI, were used to assess the associations, if any, of response with genotype. These variants did not alter GLP-1 concentrations in response to oral intake. No effects on β-cell responsiveness to hyperglycemia and GLP-1 infusion were apparent. Diabetes-associated variation (T allele at rs7903146) in TCF7L2 may impair the ability of hyperglycemia to suppress glucagon (45 ± 2 vs. 47 ± 2 vs. 60 ± 5 ng/L for CC, CT, and TT, respectively, P = 0.02). In nondiabetic subjects, diabetes-associated genetic variation does not alter GLP-1 concentrations after an oral challenge or its effect on insulin secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287 · cited 2×
“This led to the suggestion that TCF7L2 predisposed to diabetes via alterations in posttranslational processing of proglucagon to GLP-1 (7).”
BackgroundSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Prehepatic Insulin Production in Man: Kinetic Analysis Using Peripheral Connecting Peptide Behavior*
EATON, R. P., ALLEN, R. C., SCHADE, D. S., ERICKSON, K. M., & STANDEFER, J. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-520 · Cited by 363
Oral Glucose Tolerance Test Minimal Model Indexes of β-Cell Function and Insulin Sensitivity
Breda, E., Cavaghan, M. K., Toffolo, G., Polonsky, K. S., & Cobelli, C. (2001) · Diabetes · doi:10.2337/diabetes.50.1.150 · Cited by 320
Self-citationSchäfer, S. A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N., Gallwitz, B., Holst, J. J., Dekker, J. M., t’Hart, L. M., Nijpels, G., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0753-6 · Cited by 308
A model of GLP-1 action on insulin secretion in nondiabetic subjects
Dalla Man, C., Micheletto, F., Sathananthan, A., Rizza, R. A., Vella, A., & Cobelli, C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00705.2009 · Cited by 45 · cited 2×
“We recently developed a model to quantify b-cell responsivity (fTotal) to GLP-1 in vivo (13) and have also measured total and active GLP-1 concentrations in nondiabetic subjects undergoing oral glucose tolerance tests (OGTTs), providing the opportunity to examine the role of genetic variation in determining GLP-1 resp…”
BackgroundMethodSelf-citation
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“The loss of basal and GLP-1-stimulated proliferative capacity is also a feature of older human b cells (Dai et al., 2017) and appears independent of relative levels of GLP1R mRNA transcripts that were comparable in juvenile versus adult human islet b cells (Dai et al., 2017).”
BackgroundInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia
Torekov, S. S., Iepsen, E., Christiansen, M., Linneberg, A., Pedersen, O., Holst, J. J., Kanters, J. K., & Hansen, T. (2014) · Diabetes · doi:10.2337/db13-1454 · Cited by 84
Matikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H. (2014) · Diabetes Care · doi:10.2337/dc13-1283 · Cited by 63
“(29) reported in healthy individuals that TCF7L2, WFS1, and KCNQ1 genotypes had no effect on GLP-1 concentrations after an OGTT, or on b-cell responsiveness to hyperglycemic clamp and GLP-1 infusion.”
BackgroundVarghese, R. T., Viegas, I., Barosa, C., Marques, C., Shah, M., Rizza, R. A., Jones, J. G., & Vella, A. (2016) · Diabetes · doi:10.2337/db15-1593 · Cited by 25
“It remains possible that, under conditions of daily living, portal concentrations of glucagon differ between groups (19).”
BackgroundSelf-citationThe Longitudinal Effect of Diabetes-Associated Variation in TCF7L2 on Islet Function in Humans
Zeini, M., Laurenti, M. C., Egan, A. M., Muthusamy, K., Ramar, A., Vella, E., Bailey, K. R., Cobelli, C., Dalla Man, C., & Vella, A. (2024) · Diabetes · doi:10.2337/db24-0192 · Cited by 10
Self-citation
Metadata
- Authors
- Smushkin, G., Sathananthan, M., Sathananthan, A., Dalla Man, C., Micheletto, F., Zinsmeister, A. R., Cobelli, C., & Vella, A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-04-13
- Volume
- 61
- Issue
- 5
- Pages
- 1082-1089
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2152383244
- Cited by
- 43
- References
- 6
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.